GlassScriptPhysician profile
Christian Guier
NPI 1700868007
$14,925.15
in general payments reported to CMS, 2019-2025
19 companies · $6,750 in 2025
The $6,750 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $1,575 · 2021: $556 · 2022: $500 · 2023: $1,038 · 2024: $1,631 · 2025: $6,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,813 · Food and Beverage: $3,566 · Honoraria: $25.59 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,812.50 |
| Food and Beverage | $3,566.09 |
| Honoraria | $25.59 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $6,970.25 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $4,205.76 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $980.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $589.79 | 2021-2025 | Clareon, Wavelight Ex500 Excimer Laser |
| Glaukos Corporation | $431.26 | 2023-2024 | Ce-Marked Kxla System, Idose |
| Horizon Therapeutics Plc | $268.64 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $222.32 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $217.38 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.08 | 2019-2021 | |
| Shire North American Group INC | $175.68 | 2019 | |
| Sun Pharmaceutical Industries INC. | $167.96 | 2024-2025 | |
| Dutch Ophthalmic, USA | $132.75 | 2025 | Eva, Combined Machine, Tissueblue |
| Aerie Pharmaceuticals, INC. | $111.64 | 2021 | |
| Biotissue Holdings INC. | $100.30 | 2025 | |
| Abbvie INC. | $70.85 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $28.53 | 2025 | Oxervate |
| Harrow Eye, LLC | $19.77 | 2024 | Vevye |
| Amgen INC. | $17.38 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Guier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.